Halozyme looks to US restart of ViroPharma's Cinryze study to validate rHuPH20
This article was originally published in Scrip
Executive Summary
San Diego-based Halozyme Therapeutics president and CEO Gregory Frost minimised the impact of concerns surrounding Baxter's subcutaneous HyQ treatment for primary immunodeficiency disorder after the US FDA issued guidance that will allow ViroPharma to restart clinical trials for Cinryze (human C1 esterase inhibitor) using Halozyme's recombinant human hyaluronidase (rHuPH20).